Literature DB >> 16894196

High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.

Cécile Voisset1, Anne Op de Beeck, Pauline Horellou, Marlène Dreux, Thierry Gustot, Gilles Duverlie, François-Loic Cosset, Ngoc Vu-Dac, Jean Dubuisson.   

Abstract

The neutralizing activity of anti-hepatitis C virus (HCV) antibodies is attenuated by a factor present in human sera, which has been proposed to be high-density lipoproteins (HDLs). HDLs have also been shown to facilitate the entry of HCV pseudoparticles (HCVpp) into target cells. Here, the aim of the study was to determine whether HDL-mediated facilitation of HCVpp and infectious HCV (HCVcc) entry and attenuation of neutralization are two related phenomena. The data indicated that HDLs attenuate neutralization at a constant rate. In addition, as for HDL-mediated facilitation of HCVpp entry, attenuation of neutralization depended on the expression of the scavenger receptor BI (SR-BI) and its selective lipid-uptake function. Finally, kinetic experiments showed that HDL-mediated facilitation of HCVpp entry is more rapid than virus neutralization. Altogether, these observations indicate that HCV is exploiting the physiological activity of SR-BI for promoting its entry into target cells, which consequently also protects the virus against neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894196     DOI: 10.1099/vir.0.81932-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  39 in total

1.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus.

Authors:  Holly Freedman; Michael R Logan; Darren Hockman; Julia Koehler Leman; John Lok Man Law; Michael Houghton
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.

Authors:  Rolando Paciello; Richard A Urbanowicz; Gennaro Riccio; Emanuele Sasso; C Patrick McClure; Nicola Zambrano; Jonathan K Ball; Riccardo Cortese; Alfredo Nicosia; Claudia De Lorenzo
Journal:  J Gen Virol       Date:  2015-10-29       Impact factor: 3.891

6.  Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.

Authors:  Anne K Schwarz; Joe Grove; Ke Hu; Christopher J Mee; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

7.  The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus.

Authors:  Laurent Meertens; Claire Bertaux; Lisa Cukierman; Emmanuel Cormier; Dimitri Lavillette; François-Loïc Cosset; Tatjana Dragic
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

Review 8.  Targeting host factors: a novel rationale for the management of hepatitis C virus.

Authors:  Mahmoud Aboelneen Khattab
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

9.  Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity.

Authors:  Thomas J F Nieland; Jared T Shaw; Firoz A Jaipuri; Jay L Duffner; Angela N Koehler; Sotirios Banakos; Vassilis I Zannis; Tomas Kirchhausen; Monty Krieger
Journal:  Biochemistry       Date:  2007-12-08       Impact factor: 3.162

10.  Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Authors:  Marlène Dreux; Viet Loan Dao Thi; Judith Fresquet; Maryse Guérin; Zélie Julia; Géraldine Verney; David Durantel; Fabien Zoulim; Dimitri Lavillette; François-Loïc Cosset; Birke Bartosch
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.